Chronic Bronchitis

Chronic bronchitis is one of the major obstructive lung diseases that fall under the chronic obstructive pulmonary disease (COPD).  Bronchitis is divided into two sub-categories: acute (short-lived) or chronic (recurring). When an individual repeatedly suffers from a condition that causes the air passages of the lungs to become inflames, they are suffering from chronic bronchitis. The inflammation usually results from irritation or infection; when irritation or infection is present in the large and small bronchi (tree-like air passages in the lungs), the typically thin mucus linings that protect the lungs become inflamed. As a result of the increasing inflammation, the airway linings begin to leak fluids. In order to clear the airway, the body reacts by coughing, thus sufferers of chronic bronchitis often exhibit a moist, painful cough.

The 4 Stages of Chronic Bronchitis

While there are not specific stages of chronic bronchitis, many individuals use the COPD stages as a model to measure the severity of an individual’s condition. Since chronic bronchitis is one branch of COPD, it is considered acceptable, and is recommend by Global Initiative for Chronic Obstructive Lung Disease (GOLD).

People with a chronic lung disease are often monitored by their lung capacity. Due to the inflammation resulting from chronic bronchitis, it is not surprising that sufferers often struggle to breathe easily. Difficulties arise when they attempt to exhale forcefully and with the volume of air they can hold due to the lessened space. A pulmonary function test (PFT), also known as the forced expiratory volume test (FEV1) is used to monitor the amount of air an individual can expel in the first second of exhaling. This test is often performed in conjunction with a forced vital capacity test (FVC), which measure the patient’s lung volume capacity. The results of both tests are used in the following ratio to determine the severity, and resulting stage, of a patient’s chronic lung condition: FEV1/FVC.

Is It Stage 3 Chronic Bronchitis?

Stage 3 of COPD is characterized by a FEV1 test score that is greater than 30 percent, but less than or equal to 50 percent, and a FEV1/FVC ratio less than 70 percent.

Sufferers of stage 3 chronic bronchitis (and COPD) often deal with chronic coughing, increased sputum and mucus production, frequent respiratory infections, painful breathing, chest tightness, unintended weight loss and shortness of breath.

Treatment for Stage 3 Chronic Bronchitis

Patients in stage 3 of chronic bronchitis have many options to improve their quality of life. The Lung Institute offers two adult cellular therapies for stage 3 chronic bronchitis: bone marrow cellular therapy and venous (blood-derived) cellular therapy. The other hand, the venous therapy can be performed on its own when needed. During these therapies, the adult cells go through a specific process to target the damaged tissue.

Adult cells can be utilized in any organ in the body since cells are able to mimic any possible differentiated cells. Since they are capable of self-renewing indefinitely, they can divide many times and can specialize to promote the healing of organs, such as lungs, while still sustaining the original cell.

Stage 3 of Chronic Bronchitis Treatment Process

The cells are extracted from the patient’s body either through bone marrow or blood depending on the case. The cells are isolated by a trained professional in a clinical setting. The adult cells are quickly returned to the patient intravenously. Now, the cells will begin to promote the healing of lung tissue. With their ability to continually replicate, the lungs grow stronger, and patients are able to breathe easier and live better.

If you or a loved one wants to learn more about how stage 3 chronic bronchitis can be improved through cellular therapy, contact us or call us at (800) 729-3065.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.